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During cancer progression, malignant cells may evade 
immunosurveillance. However, evidence for immunological escape 
in humans is scarce. We report here the clinical course of a melanoma 
patient whose initial tumor was positive for the antigens NY-ESO-1, 
MAGE-C1, and Melan-A. Upon immunization with a recombinant 
vaccinia/fowlpox NY-ESO-1 construct, the patient experienced a 
mixed clinical response and spreading of the NY-ESO-1 epitopes in 
the CD4+ T cell compartment. After NY-ESO-1 protein + CpG 
immunization, the patient’s anti-NY-ESO-1 IgG response increased. 
Over the following years, progressing lesions were resected and found 
to be NY-ESO-1-negative while being positive for MAGE-C1, Melan-
A, and MHC-I. The fatal, inoperable brain metastasis was analyzed 
after his death and also proved to be NY-ESO-1-negative, while being 
positive for MAGE-C1 and Melan-A, as well as MHC-I. We propose 
that cancer control and cancer escape in this patient were governed by 
NY-ESO-1-specific immunological pressure. Our findings provide 
evidence for the existence of immunoediting and immunoescape in 
this cancer patient.
Keywords: NY-ESO-1, Cancer/Testis antigen, melanoma, 
immunosurveillance, escape 
Introduction
The immune system can control cancer cells through a process 
known as cancer immunosurveillance. However, tumors evolve 
with time such that they escape immune control (editing). Most 
evidence for immune-driven editing and escape was generated 
in mouse models (1, 2) and proof for the existence of such 
processes in humans is scarce. Tumor-specific peptides arise 
from mutated or uniquely expressed proteins in malignant cells, 
such as from Cancer/Testis (CT) antigens like NY-ESO-1 and 
MAGE-C1 (3). Because spontaneous responses to CT antigens 
are found in cancer patients, these antigens are thought to be 
immunogenic and therefore represent attractive targets for 
cancer immunotherapy (4-5). Accordingly, a variety of different 
NY-ESO-1 vaccines have been investigated in clinical trials (6-
12).
Here, we present an immunological characterization of a 
melanoma patient who lived almost 10 years with metastatic 
disease. The patient was treated with various forms of surgery, 
chemo-, radio-, and immunotherapy. Importantly, he was 
immunized with vaccinia/fowlpox NY-ESO-1, followed by NY-
ESO-1 protein + CpG. We found that all lesions growing out in 
the face of immunization were negative for NY-ESO-1, while 
being positive for other antigens like MAGE-C1, Melan-A, and 
MHC-I. Our findings provide evidence for the existence of 
immunoediting and -escape in this cancer patient. 
Results
Treatment history
A 61-year-old male patient (ZH-311) was diagnosed in March 
2001 with an inguinal lymph node metastasis from an occult 
primary melanoma. The clinical course of ZH-311 is 
remarkable, as he lived for more than 9 years with metastatic 
Stage IV melanoma. The treatment history is summarized in 
Figure 1. The initial tumor mass was widely excised and 
adjuvant interferon alfa-2a therapy was given. A year and a half 
after the initial diagnosis, the patient developed multiple 
mesenterial lymph node and liver metastases. A combination 
therapy with interferon alfa-2b and temozolomide was started 
and initially stabilized the disease. Upon recurrent tumor 
growth, vindesine treatment was initiated but had to be stopped 
early due to neuropathy. The tumor typed positive for NY-ESO-
1 at diagnosis and the patient fulfilled the inclusion criteria for 
the LUD 00-014 clinical trial, exploring immunization 
efficiency with a recombinant vaccinia/fowlpox NY-ESO-1 
construct (7). The immunization was initiated in May 2004 
when the patient presented with liver, lymph node, and 
peritoneal metastases. In August 2004, he came to the 
emergency room with bleeding ab ano caused by a metastasis in 
the colon. This metastasis was excised and the immunization 
was continued until a single brain metastasis was discovered in 
March 2005. This metastasis also was excised, followed by local 
irradiation. All other tumor sites at that time were regressing. In 
a follow-up scan in May 2005, a new pulmonary metastasis was 
diagnosed but, as requested by the patient, no specific treatment 
was initiated. In September 2005, the patient was offered a NY-
ESO-1 protein + CpG immunization after informed consent. In 
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Figure 1
Clinical course and treatment history of patient ZH-311.
March 2006, the then still growing lung metastasis was excised. 
No other metastases except for stable liver metastasis were 
detected by imaging and, in September 2006, it was decided to 
remove the remaining tumor in the liver. In June 2007, he 
developed a new abdominal wall metastasis upon which 
treatment with ipilimumab was initiated in July 2007 and 
continued until March 2009. An initial mild colitis resolved 
rapidly upon steroid treatment. The abdominal wall metastasis 
was surgically removed in April 2008 due to continuous growth. 
The patient died in July 2010 from a new inoperable brain 
metastasis more than 9 years after the initial diagnosis of 
metastatic melanoma.
In summary, besides the initial immuno-chemotherapy and 
adjuvant brain irradiation, the patient was treated with two NY-
ESO-1-specific immunizations, ipilimumab and five surgical 
interventions for metastatic disease to the colon, brain, lung, 
liver, and the abdominal wall. Four surgeries were performed to 
control single progressing metastases and the surgery of the 
stable liver metastasis was performed in hope to render the 
patient tumor-free (Figure 1).
Longitudinal analysis of tumor antigen and MHC-I expression in 
metastases
The inguinal lymph node metastasis, which was excised at 
initial diagnosis in March 2001, expressed the CT antigens NY-
ESO-1 and MAGE-C1, as well as Melan-A and MHC-I 
(Figure 2). Tumor sites, which were removed after 
immunization due to progressive disease (colon, brain, lung, 
and abdominal wall metastases), did not express NY-ESO-1 
(Figure 3), but the sites were MAGE-C1- and Melan-A-positive 
(Figure 4). In September 2006, the stable liver metastasis was 
removed. In contrast to the progressing metastases, the stable 
liver metastasis expressed NY-ESO-1 (Figure 3). The fatal brain 
metastasis, which was analyzed post mortem had the same 
expression profile as all the progressing tumor lesions (NY-ESO-
1-negative). Otherwise, post mortem tumor was found in the 
lungs and pulmonary lymph nodes; these tumor sites were NY-
ESO-1-negative. The liver was free of disease. All tumors 
expressed MHC-I molecules as assessed by 
immunohistochemistry. More thorough analysis of MHC-I 
alleles was not performed (13).
In conclusion, examination of NY-ESO-1 expression in 
different lesions revealed that progressing lesions after 
immunization were NY-ESO-1-negative, whereas the stable 
lesion still expressed NY-ESO-1. The expression of MHC-I, 
MAGE-C1, and Melan-A remained unchanged during the 
course of the disease. We propose that NY-ESO-1-specific 
immunity prevented the outgrowth of NY-ESO-1-positive 
tumor cells but did not impact on NY-ESO-1-negative tumor 
cells.
NY-ESO-1-specific CD8+ T cell responses and antibodies against 
NY-ESO-1
The patient was continuously lymphopenic (< 1000 
lymphocytes/μl), a condition that is often observed in cancer 
patients. CD8+ T cell responses against NY-ESO-1 were 
investigated by staining for cytokine production (IFN- and 
TNF-) and degranulation (CD107a surface expression) after in 
vitro stimulation. Initially, overlapping peptides spanning the 
entire NY-ESO-1 sequence were used and we found that the 
majority of the CD8+ T cells were specific for two peptides 
(Figure 5): aa 71-90 (peptide 3) and aa 81-100 (peptide 4), 
confirming the results obtained during the LUD 00-014 clinical 
trial. All further experiments were thus performed with the 
combination of these two peptides. A polyfunctional CD8+ T 
cell response against NY-ESO-1 was observed in peripheral 
blood mononuclear cells (PBMCs) before immunotherapy 
(patient 31 in (7)), which seemed to increase during vaccinia/
fowlpox immunization (Figure 6B and Figure 7). However, 
analyses were performed after 3 weeks of in vitro expansion, 
making the assays less quantitative. After NY-ESO-1 protein + 
CpG immunization, only the capacity to degranulate increased, 
whereas the percentage of IFN- and TNF- producing CD8+ T
Figure 2
Immunohistochemical analysis of the initial tumor biopsy. Expression of NY-ESO-1, MAGE-C1, Melan-A, and MHC-I in the initial tumor in March 2001.
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Figure 3
Immunohistochemical analysis of NY-ESO-1 expression in different biopsies.
Expression of NY-ESO-1 was present in the initial tumor in March 2001 and in the 
stable liver metastasis in 2006. All other tumor sites were negative for NY-ESO-1.
cells did not change. The cellular response was analyzed 3 weeks 
after in vitro stimulation and was mirrored by the NY-ESO-1-
specific IgG response initially (Figure 6A); however, the NY-
ESO-1-specific IgG remained high, whereas the NY-ESO-1-
specific CD8+ T cell response decreased and could not be 
boosted or recalled by immunization with NY-ESO-1 protein + 
CpG or ipilimumab (Figure 6C).
Discussion
The adaptive immune system evolved to control and eliminate 
non-self. There is ample evidence that it is able to recognize 
malignant cells as well: immunodeficient mice develop more 
carcinogen-induced cancers than wild-type mice (1, 14-17), 
tumor cells from immunodeficient mice are more immunogenic 
than those from immunocompetent mice (14), and the immune 
system of a naïve mouse can restrain cancer growth for extended 
time periods (18). Evidence for the existence of such processes 
in humans is scarce and, due to obvious reasons, indirect. 
Spontaneous tumor-specific immune responses are frequently 
detected in cancer patients (19-20) and, along this line, we 
detected an anti-NY-ESO-1 immune response in the patient 
described here. However, it is challenging to prove a causal 
relation between the existence of such responses and tumor 
control or escape (15-17). There are reports that correlate the 
quantity, quality, and spatial distribution of tumor-infiltrating 
lymphocytes (TILs) with patient survival or patient outcome 
under therapy. Remarkably, the type and density of lymphocytes 
infiltrating lung (23) or colon cancer (24) was found to be a 
more powerful prognostic indicator than previous pathological 
criteria for tumor staging. Recently, a strong association 
between immune cell density of colorectal liver metastases and 
chemotherapy response was described, highlighting the 
importance of the local immune response in metastatic 
colorectal cancer (CRC) (25). 
Immunodeficiency in organ-transplanted or in AIDS patients 
is associated with a higher risk of cancer. Although the cancers 
arising in these patients are typically those with a viral etiology 
such as lymphomas (Epstein-Barr virus), Kaposi’s sarcoma 
(herpes viruses), and cervical cancer (human papilloma 
viruses), there is at least some evidence that these patients are at 
greater risk for malignancies of the colon, lung, pancreas, 
kidney, head and neck, and endocrine system, as well as 
nonmelanoma skin cancers (26, 27).
Figure 4
Immunohistochemical analysis of the abdominal wall metastasis. Expression of NY-ESO-1, MAGE-C1, Melan-A, and MHC-I in a metastasis that was surgically 
removed in April 2008.
Cancer Immunity (15 July 2013) Vol. 13, p. 12
4 of 7 www.cancerimmunity.org
Patient ZH-311 had a spontaneous NY-ESO-1-specific 
humoral and cellular immune response, which was boosted by 
subsequent immunizations. Despite this, some lesions grew 
progressively whereas others were stable or decreased. We 
interpret the observation that NY-ESO-1 expression was lost 
selectively in progressively growing lesions as a clear indication 
for immune escape. We thus propose that persistence and 
progression of NY-ESO-1-negative cancer cells was driven by 
NY-ESO-1-specific immunological pressure. As the patient 
harbored other targetable tumor antigens, a multivalent vaccine 
(including MAGE-C1) might have prevented the outgrowth of 
NY-ESO-1-negative tumors.
In summary, these clinical observations and laboratory 
findings are consistent with the hypothesis that malignancies are 
immunoedited not only when the unmanipulated immune 
system encounters a developing tumor, but also when an 
established tumor is treated with immunotherapy.
Figure 5
Spontaneous NY-ESO-1-specific immunity in patient ZH-311. Intracellular 
staining for IFN- and TNF- and for degranulation (CD107a surface expression) 
after in vitro stimulation of ZH-311 PBMCs. Overlapping peptides spanning the 
entire NY-ESO-1 sequence were used for stimulation and readout. aa 71-90 corre-
spond to peptide 3 and aa 81-100 correspond to peptide 4.
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Materials and methods
Patient
A 61-year-old male patient (ZH-311) was diagnosed with 
metastatic melanoma with an unknown primary lesion upon 
discovery of an inguinal mass in March 2001. The clinical course 
and treatment details are given in Figure 1. The patient gave 
informed consent for analyses described in accordance with the 
Declaration of Helsinki.
Measurement of NY-ESO-1-specific CD8+ T cell responses
To characterize NY-ESO-1-specific CD8+ T cell responses in 
PBMCs and TILs during the course of disease, we performed in 
vitro stimulation with NY-ESO-1-derived overlapping peptides 
(20-mers) followed by intracellular cytokine staining. CD8+ and 
CD4+ T cells were isolated from PBMCs by positive selection 
using the MACS system (Miltenyi Biotech, Germany) according 
to manufacturer’s instructions. CD4+ and CD8+ fractions were 
> 90% pure as determined by flow cytometry (data not shown). 
The remaining CD8- CD4- fraction was irradiated (20 Gy), 
loaded with 10-6 M of each of two overlapping NY-ESO-1 
peptides (aa 71-90 and aa 81-100) and was used as antigen-
presenting cells (APCs). 4x105 CD8+ T cells were incubated for 
8 days with 4x105 peptide-loaded, irradiated APCs in 96-well 
flat bottom plates in 200 μL RPMI containing 10% heat-inactiv-
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Figure 6
Immunological parameters and clinical events. (A) NY-ESO-1-specific IgG. (B) NY-ESO-1-specific polyfunctional CD8+ T cell response. (C) Clinical events. Immuni-
zation with vaccinia/fowlpox NY-ESO-1 is indicated with (*), immunization with NY-ESO-1 + CpG with (**), and ipilumumab with (***) on the X-axes. Arrows indicate 
the time points of operation.
ated human serum, antibiotics, and 100 U/mL IL-2. During the 
same period, PHA-blasts (T-APC) were generated from CD4+ T 
cells: 106 CD4+ T cells per mL RPMI containing 10% heat-
inactivated human serum, antibiotics, and 100 U/mL IL-2 in 24-
well plates were activated with 1 μg/mL phytohaemagglutinin 
(PHA). After 8 days, T-APC were harvested and labeled with 1 
μM CFSE. The CD8+ T cell cultures were resuspended and 
incubated for 6 hours with CFSE-labeled T-APC +/- peptide 
(10-6 M) in the presence of 10 μg/mL Brefeldin A, 10 μg/mL 
monensin, 1 μg/mL anti-CD28/anti-CD49d antibodies (BD 
Biosciences), and PE-labeled anti-CD107a antibodies. After 
incubation, cells were harvested and stained with anti-CD3-
Pacific Orange, anti-CD4-APC-Cy7, anti-CD8-PE-Texas Red, 
anti-CD14-Pacific Blue, anti-CD19-Pacific Blue, and violet 
LIVE/DEAD® Fixable Dead Cell Stain Kit (Invitrogen). After 
fixing (2% formalin) and permeabilization (0.1% saponin in 
PBS), cells were stained intracellularly with anti-IFN--APC and 
anti-TNF--PE-Cy7. All antibodies were obtained from 
BioLegend or Beckman Coulter (anti-CD8-PE-Texas Red). The 
percentage CD107a+, IFN-+, TNF-+, and CD8 cells was 
determined after gating on CD3+ CD8+ cells and excluding 
dead cells (Violet-), monocytes, and B cells (CD14- and CD19-, 
respectively).
Figure 7
NY-ESO-1-specific immunity in patient ZH-311. (A) Representative flow cytometry dot plots for gating strategy. Representative flow cytometry dot plot of intracellular 
staining for IFN-, TNF-, and for degranulation (CD107a surface expression) unstimulated (B) and after in vitro stimulation (C) of ZH-311 PBMCs.
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Measurement of NY-ESO-1-specific serum IgG
We tested sera for the presence of NY-ESO-1-specific IgG with 
GST-tagged protein by ELISA. The dilutions were performed for 
each time point. ELISA was performed as described earlier (28).
Immunohistochemical analysis of the expression of NY-ESO-1, 
MHC-I, and immune infiltration of tumor samples
Tumor specimens from surgery and all tumor sites revealed in 
autopsy were analyzed by immunohistochemistry for the 
expression of NY-ESO-1 and MHC-I, as well as for CD4+ and 
CD8+ T cell infiltration. NY-ESO-1 immunohistochemistry was 
performed as recently reported (29, 30). In brief, paraffin-
embedded tissue sections were stained with mouse anti-human 
monoclonal antibodies (CD4, clone 1F6, 1:30, Zymed 
Laboratories, Inc.; CD8, clone C8/114B, 1:100, Dako A/S, 
Carpinteria, CA; MHC-I, clone 2l, 1:1000, RDI Research 
Diagnostics, Inc., this antibody does not detect all alleles; NY-
ESO-1, clone E978, 1:50, Zymed Laboratories, Inc.). UView 
(Ventana) or Refine DAB (Vision BioSystems) were used as 
chromogens against the primary antibodies. Sections were 
counterstained with hematoxylin, dehydrated, and mounted. All 
sections were stained with the Ventana BenchMark automated 
staining system (Ventana Medical Systems) using Ventana 
reagents for the entire procedure.
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